Soluble CD23 measurement by CBA: a convenient and reliable quantification method in chronic lymphocytic leukemia

Area of Science:

• Hematology
• Immunology
• Biochemistry

Background:

• Soluble CD23 (sCD23), the low-affinity IgE receptor, is elevated in chronic lymphocytic leukemia (CLL) serum.
• Increased sCD23 levels correlate with poor prognosis in CLL patients at diagnosis and during clinical follow-up.

Purpose of the Study:

• To validate the cytometric bead array (CBA) technology for quantifying soluble CD23 (sCD23) levels.
• To establish a reliable and reproducible method for sCD23 measurement in CLL patients.

Main Methods:

• Tested 420 serum samples (360 CLL patients, 60 healthy volunteers).
• Optimized antibody pairs and assay conditions for sCD23 detection using CBA.
• Correlated CBA results with enzyme-linked immunosorbent assay (ELISA) and assessed inter-laboratory reproducibility.

Main Results:

• Achieved satisfactory repeatability (CV: 5%) and reproducibility (CV: 6%) with the optimized CBA assay.
• Established a positivity threshold of 6 ng/mL for sCD23.
• Demonstrated high correlation (Spearman coefficient: 0.99) between CBA and ELISA, and between different laboratories and sample types (serum/plasma).

Conclusions:

• The CBA assay is a validated, simple, reproducible, and reliable method for sCD23 quantification.
• This assay provides clinicians with a valuable prognostic indicator for CLL diagnosis and disease monitoring.